Endocrinology

How the effective cardiovascular drug class have reach a state of impending head-to-head trials.

A prospective study found that daily dapagliflozin significantly improved mitral flow, left ventricular mass index, and left atrial volume index after 6 months of treatment.

No head-to-head trials exist for the inhibitors, but current data shows consistency across the board for each drug.

Recently new therapy options are becoming more evidenced by the day. But have they reached their fullest potential?

What drives your burnout? Better yet, how do you prevent yourself from getting burned out? Dr. Chao raises this important issue in this month's physician column.

The 100 Units/mL/ 300 mcg/mL-dosed therapy was previously approved as an add-on therapy to diet and exercise in adults with T2D.

The t:Slim X2 insulin pump is both compatible with outside therapy systems, and capable of delivering insulin on its own.

The CAROLINA cardiovascular safety study found that linagliptin was non-inferior to glimepiride in time to a composite cardiovascular endpoint.

Advanced hepatitis C virus patients with HIV infection recover liver function with all-oral direct‐acting antivirals (DAA) therapy, study shows.

In the past 5 years, the administration has continually improved on the previous year's rate. More of the same should be anticipated in 2019.

Statins are already a common therapy among patients with type 2 diabetes. Its cholesterol-lowering benefits may help retain patient vision longer.

The investigative SGLT1/2 dual inhibitor is scheduled to be considered for marketing approval by mid-March.

Authors of a new study found that liraglutide lowers blood pressure, but which T2DM patients benefit most and how?

Once one of the country healthcare system's greatest successes, CVD and related mortality is rising again. What's its true cause?

Three new studies from Obesity Week 2018 highlight non-surgical weight loss strategies for obese patients. 

A new study found that elevated free thyroxine within the upper range of normal may increase risk of AF; is may be time to redefine what is "safe" when treating hypothyroidism.

Three new studies from Obesity Week 2018 offered highlights of different surgical interventions for obese patients.

True or false? Clinicians should use 2 growth hormone stimulation tests to diagnose patients suspected of idiopathic AGHD. Answer plus 5 more.

Adult growth hormone deficiency treatment is safe and effective, but who is tracking the social and economic impact, reviewers ask?

Patients with diabetic macular edema who do not show sufficient progress after anti-VEGF-A treatment may soon have a new option.

What is the classic triad of symptoms that can be considered pathognomonic for pheochromocytoma? Answer and 4 more questions in this short test.

Wiviott, senior investigator of the DECLARE-TIMI 58 trial, says that SGLT2 inhibitors and GLP-1 receptor agonists are changing the paradigm of how clinicians manage diabetes and cardiovascular risk.

Topline data shows that the diabetes medication is non-inferior to placebo with regard to a composite outcome of major adverse cardiovascular events.

How fatty liver disease and NASH—as well as the comorbidities associated with them—highlighted this year's discussions.

Authors of a new study have found that widespread use of ultrasound increases the diagnosis of low-risk thyroid cancers and may lead to harm following thyroid surgery.